ABSTRACT
BACKGROUND: The COVID-19 (SARS-CoV-2) pandemic has increased infection control vigilance across several modes of patient contact. However, it is unknown whether hygiene pertaining to stethoscopes, which carry the potential for pathogenic contamination, has also shifted accordingly. AIM: To characterize pandemic-related changes in stethoscope hygiene. METHODS: We surveyed healthcare providers at three major medical centres. Questions quantitatively (Likert scale and frequency) assessed stethoscope hygiene beliefs and practices with two components: before and during COVID-19. Participants were grouped based on performance of optimal stethoscope hygiene (after every patient) before and during COVID-19. Groups were compared using χ2 and analysis of variance (ANOVA). FINDINGS: Of the 515 (10%) who completed the survey, 55 were excluded (N = 460). Optimal hygiene increased from 27.4% to 55.0% (P < 0.001). There were significant increases in Likert scores for all questions pertaining to knowledge of stethoscope contamination (P < 0.001). Belief in stethoscope contamination increased (P < 0.001) despite no change in perceived hygiene education. Resident physicians were less likely compared with attending physicians and nurses to have adopted optimal hygiene during COVID-19 (P < 0.001). CONCLUSION: Despite a positive shift in stethoscope hygiene during COVID-19, optimal hygiene was still only performed by around half of providers. Educational interventions, particularly targeting early-career providers, are encouraged.
Subject(s)
COVID-19 , Stethoscopes , COVID-19/prevention & control , Cross-Sectional Studies , Disinfection , Humans , Hygiene , SARS-CoV-2ABSTRACT
MedPics is a computer-based image delivery system with supporting text fields and on-screen graphics to assist in key feature identification. It has been used by the University of California, San Diego as an integral part of the Human Disease course since 1992. Initially created to support pathology and histology, the program has now expanded to include hematology. MedPics has had a positive impact on the second year curriculum for which it was created. Moreover, use of this program has improved student attitudes toward computer-based resources and increased faculty interest in instructional development.
Subject(s)
Computer-Assisted Instruction , Education, Medical, Undergraduate , Image Processing, Computer-Assisted , California , Curriculum , Hematology/education , Histology/education , Humans , Pathology/education , Program Evaluation , Schools, MedicalABSTRACT
We have reported a case of unilateral lower extremity hypertrophic osteoarthropathy (HOA) associated with vascular graft infection, and have reviewed previous reports of this association. Knowledge of this association may lead to earlier diagnosis of graft infection in patients with clinical evidence of HOA.
Subject(s)
Aorta, Abdominal/surgery , Osteoarthropathy, Secondary Hypertrophic/etiology , Surgical Wound Infection/complications , Aged , Humans , MaleABSTRACT
One hundred nineteen patients with primary and 31 patients with nonprimary first-episode genital herpes were treated for ten days with 200 mg of acyclovir capsules or placebo capsules orally five times daily. Among acyclovir recipients with primary genital herpes, the median duration of viral shedding (two days), time to crusting of all lesions (seven days), time to healing of all lesions (12 days), and duration of local pain (five days) and constitutional symptoms (three days) were shorter than among placebo recipients (9, 10, 16, 7, and 6 days, respectively). Among patients with nonprimary first-episode genital herpes, oral acyclovir shortened the median duration of viral shedding but had no significant effect on the duration of lesions or symptoms. The time to first recurrence and frequency of recurrences were similar in acyclovir- and placebo-treated patients. Oral acyclovir treatment of primary first-episode genital herpes shortens the duration of viral shedding and symptoms and accelerates healing, but it does not appear to influence subsequent genital recurrences.
Subject(s)
Acyclovir/administration & dosage , Herpes Genitalis/drug therapy , Acyclovir/adverse effects , Acyclovir/therapeutic use , Administration, Oral , Adult , Clinical Trials as Topic , Double-Blind Method , Female , Herpes Genitalis/microbiology , Herpes Genitalis/pathology , Humans , Male , Simplexvirus/isolation & purificationABSTRACT
Two hundred fifty patients were entered into a multicenter trial to evaluate the efficacy and toxicity of orally administered acyclovir for treatment of recurrent genital herpes. The study consisted of part A, in which patients entered the study within 48 hours of the onset of lesions, and part B, in which patients self-initiated therapy as soon as possible after the onset of a recurrent episode. In both parts, patients received either acyclovir (200 mg) or placebo, five times daily for five days. In both parts, the duration of virus shedding and the time to crusting and healing of lesions were shorter among acyclovir recipients than among placebo recipients. In part B, fewer acyclovir recipients formed new lesions during the study medication period than did placebo recipients. When parts A and B were compared directly, the duration of virus shedding and the times required for crusting and healing of lesions were significantly shorter among acyclovir recipients in part B than among acyclovir recipients in part A. No significant differences in the duration of itching and pain or in the times of subsequent recurrence were noted between acyclovir and placebo groups in either part A or part B. No significant toxic or adverse reactions were seen in acyclovir recipients. Oral acyclovir shortens the duration of virus shedding and the duration of lesions in patients with recurrent genital herpes. These effects are more pronounced when therapy is self-initiated by patients early in the course of a recurrent episode.
Subject(s)
Acyclovir/administration & dosage , Herpes Genitalis/drug therapy , Acyclovir/adverse effects , Acyclovir/therapeutic use , Administration, Oral , Adult , Clinical Trials as Topic , Double-Blind Method , Female , Herpes Genitalis/diagnosis , Herpes Genitalis/microbiology , Humans , Male , RecurrenceSubject(s)
Catheterization/adverse effects , Indium , Peritoneal Dialysis/adverse effects , Peritonitis/diagnostic imaging , Radioisotopes , Catheterization/instrumentation , Evaluation Studies as Topic , Humans , Leukocytes , Male , Middle Aged , Peritoneal Dialysis/instrumentation , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Peritoneal Dialysis, Continuous Ambulatory/instrumentation , Peritonitis/etiology , Radionuclide ImagingABSTRACT
A randomized, placebo-controlled, double-blind study was performed to evaluate the efficacy and toxicity of orally administered acyclovir in the treatment of patients with recurrent herpes simplex genitalis (HSG). A total of 107 patients from centers in Burlington, Vermont, and San Diego, California, were entered into the study within 48 hours of the onset of lesions. Patients who received acyclovir shed virus for 1.8 +/- 0.6 days (mean +/- SEM) compared with 2.8 +/- 1.2 days for those who received placebo. The duration of shedding from genital lesions of patients in the acyclovir-treated group was significantly less than from lesions of patients who received placebo (p = 0.016 by a logrank test). An analysis of the toxicity of the drug was performed in 52 of the study participants. Acyclovir was well-tolerated and no alterations were observed in measurements of bone marrow, liver, or kidney function. Orally administered acyclovir is a promising antiviral compound for the treatment of recurrent HSG.
